
Aditi Dutt
Examiner (ID: 3991)
| Most Active Art Unit | 1649 |
| Art Unit(s) | 1675, 1649 |
| Total Applications | 617 |
| Issued Applications | 221 |
| Pending Applications | 75 |
| Abandoned Applications | 327 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19081899
[patent_doc_number] => 20240108700
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => Methods of Treating a Spastic Disorder in a Subject Having Underlying Condition(s)
[patent_app_type] => utility
[patent_app_number] => 18/540403
[patent_app_country] => US
[patent_app_date] => 2023-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8281
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18540403
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/540403 | Methods of Treating a Spastic Disorder in a Subject Having Underlying Condition(s) | Dec 13, 2023 | Abandoned |
Array
(
[id] => 19187853
[patent_doc_number] => 20240166766
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => NOVEL ANTI-A2AP ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/525736
[patent_app_country] => US
[patent_app_date] => 2023-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30160
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18525736
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/525736 | Anti-A2AP antibodies and uses thereof | Nov 29, 2023 | Issued |
Array
(
[id] => 19065709
[patent_doc_number] => 20240100135
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => Methods of Treating an Optic Disease in a Subject
[patent_app_type] => utility
[patent_app_number] => 18/521777
[patent_app_country] => US
[patent_app_date] => 2023-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8281
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18521777
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/521777 | Methods of Treating an Optic Disease in a Subject | Nov 27, 2023 | Abandoned |
Array
(
[id] => 18816029
[patent_doc_number] => 20230390368
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s)
[patent_app_type] => utility
[patent_app_number] => 18/455179
[patent_app_country] => US
[patent_app_date] => 2023-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8281
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18455179
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/455179 | Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s) | Aug 23, 2023 | Abandoned |
Array
(
[id] => 19187829
[patent_doc_number] => 20240166742
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => MOLECULES THAT BIND TO AND STABILIZE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 (TREM2)
[patent_app_type] => utility
[patent_app_number] => 18/363237
[patent_app_country] => US
[patent_app_date] => 2023-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33367
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18363237
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/363237 | MOLECULES THAT BIND TO AND STABILIZE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 (TREM2) | Jul 31, 2023 | Pending |
Array
(
[id] => 18877537
[patent_doc_number] => 20240000906
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s)
[patent_app_type] => utility
[patent_app_number] => 18/359633
[patent_app_country] => US
[patent_app_date] => 2023-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8284
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18359633
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/359633 | Methods of Treating or Preventing Migraine or Repetitive Occurrence of Common Migraine Headaches in a Subject Having Underlying Condition(s) | Jul 25, 2023 | Pending |
Array
(
[id] => 18626747
[patent_doc_number] => 20230285553
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => MATERIALS AND METHODS FOR MITIGATING IMMUNE-SENSITIZATION
[patent_app_type] => utility
[patent_app_number] => 18/309011
[patent_app_country] => US
[patent_app_date] => 2023-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15259
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18309011
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/309011 | MATERIALS AND METHODS FOR MITIGATING IMMUNE-SENSITIZATION | Apr 27, 2023 | Pending |
Array
(
[id] => 18971971
[patent_doc_number] => 20240052063
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => Binding Proteins 2
[patent_app_type] => utility
[patent_app_number] => 18/069124
[patent_app_country] => US
[patent_app_date] => 2022-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26193
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18069124
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/069124 | Binding Proteins 2 | Dec 19, 2022 | Pending |
Array
(
[id] => 18612415
[patent_doc_number] => 20230279147
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => H1.0K180ME2 ANTIBODIES, METHODS OF MAKING AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/054427
[patent_app_country] => US
[patent_app_date] => 2022-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23329
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054427
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054427 | H1.0K180ME2 ANTIBODIES, METHODS OF MAKING AND USES THEREOF | Nov 9, 2022 | Pending |
Array
(
[id] => 18628252
[patent_doc_number] => 20230287106
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => NOVEL COMPOUNDS CAPABLE OF ANTAGONIZING ISLET AMYLOID POLYPEPTIDE (IAPP) INDUCED BETA-CELL DAMAGE AND IMPAIRED GLUCOSE TOLERANCE
[patent_app_type] => utility
[patent_app_number] => 18/053842
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12273
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053842
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/053842 | NOVEL COMPOUNDS CAPABLE OF ANTAGONIZING ISLET AMYLOID POLYPEPTIDE (IAPP) INDUCED BETA-CELL DAMAGE AND IMPAIRED GLUCOSE TOLERANCE | Nov 8, 2022 | Pending |
Array
(
[id] => 18376243
[patent_doc_number] => 20230151326
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => Simplified Compositions and Methods for Generating Neural Stem Cells from Human Pluripotent Stem Cells
[patent_app_type] => utility
[patent_app_number] => 17/973020
[patent_app_country] => US
[patent_app_date] => 2022-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17973020
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/973020 | Simplified Compositions and Methods for Generating Neural Stem Cells from Human Pluripotent Stem Cells | Oct 24, 2022 | Pending |
Array
(
[id] => 19691301
[patent_doc_number] => 20250009846
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => RECOMBINANT PROTEIN OF NERVE GROWTH FACTOR MUTANT AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/686041
[patent_app_country] => US
[patent_app_date] => 2022-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15779
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18686041
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/686041 | RECOMBINANT PROTEIN OF NERVE GROWTH FACTOR MUTANT AND USE THEREOF | Aug 23, 2022 | Abandoned |
Array
(
[id] => 17981065
[patent_doc_number] => 20220347101
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => ENZYME DELIVERY SYSTEMS AND METHODS OF PREPARATION AND USE
[patent_app_type] => utility
[patent_app_number] => 17/864285
[patent_app_country] => US
[patent_app_date] => 2022-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17225
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17864285
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/864285 | ENZYME DELIVERY SYSTEMS AND METHODS OF PREPARATION AND USE | Jul 12, 2022 | Pending |
Array
(
[id] => 17990200
[patent_doc_number] => 20220356237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => ANTI-SECRETOGRANIN III (SCG3) ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/853108
[patent_app_country] => US
[patent_app_date] => 2022-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22013
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853108
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/853108 | ANTI-SECRETOGRANIN III (SCG3) ANTIBODIES AND USES THEREOF | Jun 28, 2022 | Abandoned |
Array
(
[id] => 17981285
[patent_doc_number] => 20220347321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => EXPRESSION OF NEUROPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/809376
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31535
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17809376
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/809376 | EXPRESSION OF NEUROPEPTIDES | Jun 27, 2022 | Pending |
Array
(
[id] => 18389910
[patent_doc_number] => 20230158128
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC AND NEUROLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/850383
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15217
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850383
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850383 | CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC AND NEUROLOGICAL DISORDERS | Jun 26, 2022 | Pending |
Array
(
[id] => 17991276
[patent_doc_number] => 20220357313
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => DRUG FINGERPRINTING
[patent_app_type] => utility
[patent_app_number] => 17/735782
[patent_app_country] => US
[patent_app_date] => 2022-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18089
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17735782
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/735782 | DRUG FINGERPRINTING | May 2, 2022 | Pending |
Array
(
[id] => 17928450
[patent_doc_number] => 20220323575
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => NOVEL MILK ALLERGY ANTIGEN
[patent_app_type] => utility
[patent_app_number] => 17/708653
[patent_app_country] => US
[patent_app_date] => 2022-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31040
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 647
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17708653
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/708653 | NOVEL MILK ALLERGY ANTIGEN | Mar 29, 2022 | Pending |
Array
(
[id] => 17807767
[patent_doc_number] => 20220259602
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => INCREASING ATOH1 LIFE TO DRIVE SENSORINEURAL HAIR CELL DIFFERENTIANTION
[patent_app_type] => utility
[patent_app_number] => 17/686734
[patent_app_country] => US
[patent_app_date] => 2022-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21579
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17686734
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/686734 | Increasing Atoh1 life to drive sensorineural hair cell differentiation | Mar 3, 2022 | Issued |
Array
(
[id] => 18108108
[patent_doc_number] => 20230000988
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => Therapeutic Protein Formulations
[patent_app_type] => utility
[patent_app_number] => 17/676085
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6767
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17676085
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/676085 | Therapeutic Protein Formulations | Feb 17, 2022 | Pending |